03:45 PM EDT, 05/10/2024 (MT Newswires) -- Eli Lilly ( LLY ) could partner with Indian drugmaker Cipla to market its weight-loss drugs in India, Reuters reported Friday, citing Cipla's Global CEO Umang Vohra.

Cipla has an existing partnership to distribute and market Lilly's diabetes medicines in India, according to the report.

Global demand for Eli Lilly's ( LLY ) Mounjaro and Zepbound, targeting type 2 diabetes and effective in reducing weight, has surpassed supply. Cipla and other Indian firms are developing their versions to enter this lucrative market, Reuters said.

Eli previously told Reuters it expects to launch its weight-loss drug in India as early as next year.

Neither Eli Lilly ( LLY ) nor Cipla immediately responded to requests for comment by MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 762.16, Change: -9.39, Percent Change: -1.22